Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare

Summary

To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy

Timeline

Start

2023-07-21

Primary completion

2024-02-28

Completion

2024-02-28

Outcome

Met primary endpoint

paper Firsekibart was non-inferior and superior to etoricoxib in change from baseline in target joint pain VAS scores at 72 h post-treatment PMID 40833487 ↗

Publications

• Kong N, Xue Y, Mao L, Qian L, Guo H, Hu J, Yuan F, Li R, Duan X, Yu J, Gou W, Yang L, Wei H, Li R, Xu Q, Luo T, Zhang X, Zou H. Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority Trial. Rheumatol Ther. 2025 Oct;12(5):975-990. doi: 10.1007/s40744-025-00790-6. Epub 2025 Aug 20.

Drugs

Indications